{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T06:38:34Z","timestamp":1794119914802,"version":"4.8.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.urolonc.2024.06.002","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T11:54:15Z","timestamp":1721044455000},"page":"29-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["A systematic review of family history, race\/ethnicity, and genetic risk on prostate cancer detection and outcomes: Considerations in PSA-based screening"],"prefix":"10.1016","volume":"43","author":[{"given":"Nathan J.","family":"Graham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley H.","family":"Souter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7461-7079","authenticated-orcid":false,"given":"Simpa S.","family":"Salami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.06.002_bib0001","series-title":"USCS data brief, no. 34","article-title":"Prostate Cancer Incidence by Age and Stage at Diagnosis, United States\u20142001\u22122019","year":"2023"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.002_bib0002","first-page":"45","article-title":"Early detection of prostate cancer: AUA\/SUO guideline part I: prostate cancer screening","volume":"210","author":"Wei","year":"2023","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.06.002_bib0003","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.3390\/curroncol30020178","article-title":"Underlying Features of Prostate Cancer-Statistics, Risk Factors, and Emerging Methods for Its Diagnosis","volume":"30","author":"Berenguer","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.urolonc.2024.06.002_bib0004","doi-asserted-by":"crossref","DOI":"10.1177\/11769351231168006","article-title":"Quantifying the Contributions of Environmental Factors to Prostate Cancer and Detecting Risk-Related Diet Metrics and Racial Disparities","volume":"22","author":"Zhang","year":"2023","journal-title":"Cancer Inform"},{"issue":"7","key":"10.1016\/j.urolonc.2024.06.002_bib0005","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/pros.24320","article-title":"Neighborhood deprivation and risk of mortality among men with prostate cancer: Findings from a long-term follow-up study","volume":"82","author":"K","year":"2022","journal-title":"Prostate"},{"issue":"22","key":"10.1016\/j.urolonc.2024.06.002_bib0006","doi-asserted-by":"crossref","first-page":"5815","DOI":"10.3390\/cancers13225815","article-title":"A Polygenic Risk Score Predicts Incident Prostate Cancer Risk in Older Men but Does Not Select for Clinically Significant Disease","volume":"13","author":"Bakshi","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.urolonc.2024.06.002_bib0007","article-title":"Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews","volume":"7","author":"Shea","year":"2007","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.urolonc.2024.06.002_bib0008","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.002_bib0009","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7326\/M18-1376","article-title":"PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies","volume":"170","author":"Wolff","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.urolonc.2024.06.002_bib0010","first-page":"1","article-title":"Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments","author":"McGuinness","year":"2020","journal-title":"Res Synth Methods"},{"issue":"12","key":"10.1016\/j.urolonc.2024.06.002_bib0011","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/pros.23200","article-title":"Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial","volume":"76","author":"Chen","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2024.06.002_bib0012","doi-asserted-by":"crossref","DOI":"10.1177\/17562872221088536","article-title":"Predictors of clinically significant prostate cancer in biopsy-na\u00efve and prior negative biopsy men with a negative prostate MRI: improving MRI-based screening with a novel risk calculator","volume":"14","author":"van Riel","year":"2022","journal-title":"Ther Adv Urol"},{"issue":"10","key":"10.1016\/j.urolonc.2024.06.002_bib0013","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/pros.24537","article-title":"Development and validation of a simple prostate cancer risk prediction model based on age, family history, and polygenic risk","volume":"83","author":"Dite","year":"2023","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/j.urolonc.2024.06.002_bib0014","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1200\/JCO.22.01453","article-title":"CanRisk-Prostate: A Comprehensive, Externally Validated Risk Model for the Prediction of Future Prostate Cancer","volume":"41","author":"Nyberg","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.06.002_bib0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.euros.2022.09.001","article-title":"Reliability of Ancestry-specific Prostate Cancer Genetic Risk Score in Four Racial and Ethnic Populations","volume":"45","author":"Shi","year":"2022","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.002_bib0016","doi-asserted-by":"crossref","first-page":"e2144027","DOI":"10.1001\/jamanetworkopen.2021.44027","article-title":"Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System [published correction appears in JAMA Netw Open. 2022;5(2):e222773","volume":"5","author":"Yamoah","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.urolonc.2024.06.002_bib0017","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10552-014-0402-6","article-title":"The association between race and prostate cancer risk on initial biopsy in an equal access, multiethnic cohort","volume":"25","author":"Gaines","year":"2014","journal-title":"Cancer Causes Control"},{"issue":"7","key":"10.1016\/j.urolonc.2024.06.002_bib0018","doi-asserted-by":"crossref","first-page":"330.e9","DOI":"10.1016\/j.urolonc.2015.03.018","article-title":"Earlier prostate-specific antigen testing in African American men\u2013Clinical support for the recommendation","volume":"33","author":"Saltzman","year":"2015","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.002_bib0019","article-title":"Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing","volume":"6","author":"Giri","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.002_bib0020","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1200\/OP.21.00412","article-title":"Prostate Cancer Disparities in Risk Group at Presentation and Access to Treatment for Asian Americans, Native Hawaiians, and Pacific Islanders: A Study With Disaggregated Ethnic Groups","volume":"18","author":"Jain","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"5","key":"10.1016\/j.urolonc.2024.06.002_bib0021","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/annonc\/mdx041","article-title":"Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States","volume":"28","author":"Mahal","year":"2017","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.urolonc.2024.06.002_bib0022","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jamaoncol.2022.2970","article-title":"Association Between Prostate-Specific Antigen Screening and Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White US Veterans","volume":"8","author":"Sherer","year":"2022","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.06.002_bib0023","doi-asserted-by":"crossref","first-page":"367.e19","DOI":"10.1016\/j.urolonc.2021.02.023","article-title":"Prostate cancer outcomes disparities: Population survival analysis in an ethnically diverse nation","volume":"39","author":"Matti","year":"2021","journal-title":"Urol Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2024.06.002_bib0024","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1158\/1055-9965.EPI-22-0443","article-title":"Association of Prostate-Specific Antigen Levels with Prostate Cancer Risk in a Multiethnic Population: Stability Over Time and Comparison with Polygenic Risk Score","volume":"31","author":"Chou","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"10.1016\/j.urolonc.2024.06.002_bib0025","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41416-021-01675-5","article-title":"BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis","volume":"126","author":"Nyberg","year":"2022","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2024.06.002_bib0026","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.eururo.2014.01.003","article-title":"Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study [published correction appears in Eur Urol. 2015 Jun;67(6):e126]","volume":"66","author":"Bancroft","year":"2014","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.urolonc.2024.06.002_bib0027","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.annonc.2020.06.025","article-title":"Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening","volume":"31","author":"Segal","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.06.002_bib0028","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2021.12.023","article-title":"A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry","volume":"81","author":"Darst","year":"2022","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.002_bib0029","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkab097","article-title":"DNA Repair Pathways and Their Association With Lethal Prostate Cancer in African American and European American Men","volume":"6","author":"Plym","year":"2021","journal-title":"JNCI Cancer Spectr"},{"issue":"4","key":"10.1016\/j.urolonc.2024.06.002_bib0030","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10689-014-9744-1","article-title":"High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry","volume":"13","author":"Rosty","year":"2014","journal-title":"Fam Cancer"},{"key":"10.1016\/j.urolonc.2024.06.002_bib0031","article-title":"Germline Variants in DNA Damage Repair Genes and HOXB13 Among Black Patients With Early-Onset Prostate Cancer","volume":"6","author":"Trendowski","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.06.002_bib0032","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ijc.33324","article-title":"Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patients","volume":"148","author":"Wu","year":"2021","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2024.06.002_bib0033","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2018.11.015","article-title":"Homeobox B13 G84E Mutation and Prostate Cancer Risk","volume":"75","author":"Nyberg","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.06.002_bib0034","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41391-019-0181-y","article-title":"Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT","volume":"23","author":"Ahmed","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.urolonc.2024.06.002_bib0035","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.eururo.2013.07.005","article-title":"A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng\/ml","volume":"65","author":"Nordstr\u00f6m","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.002_bib0036","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkac001","article-title":"Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate Biopsy","volume":"6","author":"Akamatsu","year":"2022","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.002_bib0037","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41698-022-00266-8","article-title":"Prostate cancer polygenic risk score and prediction of lethal prostate cancer","volume":"6","author":"Klein","year":"2022","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.002_bib0038","doi-asserted-by":"crossref","first-page":"4863","DOI":"10.1038\/s41467-023-39858-8","article-title":"Androgen receptor binding sites enabling genetic prediction of mortality due to prostate cancer in cancer-free subjects","volume":"14","author":"Ito","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2024.06.002_bib0039","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.euros.2023.01.012","article-title":"Addition of a Genetic Risk Score for Identification of Men with a Low Prostate-specific Antigen Level in Midlife at Risk of Developing Lethal Prostate Cancer","volume":"50","author":"Ma","year":"2023","journal-title":"Eur Urol Open Sci"},{"issue":"2","key":"10.1016\/j.urolonc.2024.06.002_bib0040","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3892\/mmr.2022.12787","article-title":"Role of single nucleotide polymorphisms of the HSD3B1 gene (rs6203 and rs33937873) in the prediction of prostate cancer risk","volume":"26","author":"Amrousy","year":"2022","journal-title":"Mol Med Rep"},{"issue":"2","key":"10.1016\/j.urolonc.2024.06.002_bib0041","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41391-021-00403-7","article-title":"Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24","volume":"25","author":"Karunamuni","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.urolonc.2024.06.002_bib0042","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/jnci\/djac199","article-title":"Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program","volume":"115","author":"Pagadala","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.urolonc.2024.06.002_bib0043","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3390\/jcm12041343","article-title":"The Combined Effect of Polygenic Risk Score and Prostate Health Index in Chinese Men Undergoing Prostate Biopsy","volume":"12","author":"Ruan","year":"2023","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.urolonc.2024.06.002_bib0044","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/gim.2014.192","article-title":"Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis","volume":"17","author":"Pashayan","year":"2015","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.002_bib0045","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4111\/icu.20210305","article-title":"Prediction of clinically significant prostate cancer using polygenic risk models in Asians","volume":"63","author":"Song","year":"2022","journal-title":"Investig Clin Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2024.06.002_bib0046","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/bjc.2015.289","article-title":"Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC","volume":"113","author":"Pashayan","year":"2015","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.urolonc.2024.06.002_bib0047","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002998","article-title":"Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study","volume":"16","author":"Callender","year":"2019","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.urolonc.2024.06.002_bib0048","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41391-020-00311-2","article-title":"Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer","volume":"24","author":"Karunamuni","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.urolonc.2024.06.002_bib0049","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41391-022-00497-7","article-title":"Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score","volume":"25","author":"Huynh-Le","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"11","key":"10.1016\/j.urolonc.2024.06.002_bib0050","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.3390\/genes13112039","article-title":"Risk Allele Frequency Analysis and Risk Prediction of Single-Nucleotide Polymorphisms for Prostate Cancer","volume":"13","author":"Yoon","year":"2022","journal-title":"Genes (Basel)"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.002_bib0051","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13059-022-02766-z","article-title":"Testing the generalizability of ancestry-specific polygenic risk scores to predict prostate cancer in sub-Saharan Africa","volume":"23","author":"Kim","year":"2022","journal-title":"Genome Biol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.06.002_bib0052","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.ajhg.2022.03.008","article-title":"Polygenic risk for prostate cancer: Decreasing relative risk with age but little impact on absolute risk","volume":"109","author":"Schaid","year":"2022","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.urolonc.2024.06.002_bib0053","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.eururo.2021.12.011","article-title":"Defining the Impact of Family History on Detection of High-grade Prostate Cancer in a Large Multi-institutional Cohort","volume":"82","author":"Clements","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.06.002_bib0054","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.urolonc.2024.06.002_bib0055","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1002\/cam4.4787","article-title":"Race-specific prostate cancer outcomes in a cohort of military health care beneficiaries undergoing surgery: 1990-2017","volume":"11","author":"Oehrlein","year":"2022","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.urolonc.2024.06.002_bib0056","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/S0022-5347(05)64276-0","article-title":"Screening for prostate cancer in high risk populations","volume":"168","author":"Catalona","year":"2002","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.06.002_bib0057","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s13187-023-02326-4","article-title":"Training Community African American and Hispanic\/Latino\/a Advocates on Prostate Cancer (PCa): a Multicultural and Bicoastal Approach","volume":"38","author":"Aristizabal","year":"2023","journal-title":"J Cancer Educ"},{"issue":"5","key":"10.1016\/j.urolonc.2024.06.002_bib0058","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1002\/cam4.5405","article-title":"Factors that influence treatment decisions: A qualitative study of racially and ethnically diverse patients with low- and very-low risk prostate cancer","volume":"12","author":"Guan","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.urolonc.2024.06.002_bib0059","doi-asserted-by":"crossref","unstructured":"Frego N, Beatrici E, Labban M, et al. Racial Disparities in Prostate Cancer Screening: The Role of Shared Decision Making. Am J Prev Med. 2024 66(1):27\u201336. https:\/\/doi.org\/10.1016\/j.amepre.2023.08.005. Epub 2023 Aug 9. PMID: 37567369.","DOI":"10.1016\/j.amepre.2023.08.005"},{"issue":"8","key":"10.1016\/j.urolonc.2024.06.002_bib0060","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1200\/OP.23.00040","article-title":"Disparities in Diagnosis, Treatment Access, and Time to Treatment Among Hispanic Men With Metastatic Prostate Cancer","volume":"19","author":"Hougen","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"6","key":"10.1016\/j.urolonc.2024.06.002_bib0061","first-page":"435","article-title":"Race-insurance disparities in prostate patients\u2019 magnetic resonance imaging biopsies and their subsequent cancer care: a New York State cohort study","volume":"9","author":"Chandra","year":"2021","journal-title":"Am J Clin Exp Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.06.002_bib0062","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1200\/OP.22.00634","article-title":"Racial Differences in Germline Genetic Testing for Prostate Cancer: A Systematic Review [published correction appears in JCO Oncol Pract. 2023 Oct;19(10):940]","volume":"19","author":"Briggs","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"10.1016\/j.urolonc.2024.06.002_bib0063","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jamaoncol.2022.5511","article-title":"Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials: A Meta-analysis","volume":"9","author":"Riaz","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2024.06.002_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2022.100986","article-title":"An evaluation of race-based representation among men participating in clinical trials for prostate cancer and erectile dysfunction","volume":"29","author":"Saltzman","year":"2022","journal-title":"Contemp Clin Trials Commun"},{"issue":"4","key":"10.1016\/j.urolonc.2024.06.002_bib0065","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/bju.13416","article-title":"Prevalence of the HOXB13 G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness","volume":"118","author":"Storebjerg","year":"2016","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.urolonc.2024.06.002_bib0066","doi-asserted-by":"crossref","first-page":"542","DOI":"10.21873\/cdp.10139","article-title":"Variants in HOXB13, G132E and F127C, Are Associated With Prostate Cancer Risk in Japanese Men","volume":"2","author":"Kurihara","year":"2022","journal-title":"Cancer Diagn Progn"},{"key":"10.1016\/j.urolonc.2024.06.002_bib0067","unstructured":"Mitra et al. (2017) reported a PPV of 47.6% (10\/21) when offering men with FH of BRCA1\/2 mutations and PSA >3 were offered PB. Over a 33-month follow-up, 82% of detected PCa were in mutation carriers and 73% of detected PCa were csPCa."},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.002_bib0068","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study","volume":"77","author":"Nyberg","year":"2020","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.06.002_bib0069","doi-asserted-by":"crossref","first-page":"253.e21","DOI":"10.1016\/j.urolonc.2023.02.006","article-title":"Determinants of widespread metastases and of metastatic tropism in patients with prostate cancer: A genomic analysis of primary and metastatic tumors","volume":"41","author":"Alshalalfa","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2024.06.002_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104738","article-title":"BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype","volume":"95","author":"Fettke","year":"2023","journal-title":"EBioMedicine"},{"issue":"21","key":"10.1016\/j.urolonc.2024.06.002_bib0071","doi-asserted-by":"crossref","first-page":"13426","DOI":"10.3390\/ijms232113426","article-title":"Characteristics of BRCA2 Mutated Prostate Cancer at Presentation","volume":"23","author":"Han","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.urolonc.2024.06.002_bib0072","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1002\/cam4.5333","article-title":"The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: The multi-institutional observational ZENSHIN study","volume":"12","author":"Uemura","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.002_bib0073","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3390\/cancers14010223","article-title":"Genetic Analysis Reveals the Prognostic Significance of the DNA Mismatch Repair Gene MSH2 in Advanced Prostate Cancer","volume":"14","author":"Chang","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.urolonc.2024.06.002_bib0074","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ajur.2016.09.002","article-title":"Mismatch repair enzyme expression in primary and castrate resistant prostate cancer","volume":"3","author":"Nghiem","year":"2016","journal-title":"Asian J Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2024.06.002_bib0075","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/his.14645","article-title":"Histopathological and genetic features of mismatch repair-deficient high-grade prostate cancer","volume":"80","author":"Wyvekens","year":"2022","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.urolonc.2024.06.002_bib0076","doi-asserted-by":"crossref","first-page":"600.e17","DOI":"10.1016\/j.urolonc.2020.02.012","article-title":"The impact of TP53BP1 and MLH1 on metastatic capability in cases of locally advanced prostate cancer and their usefulness in clinical practice","volume":"38","author":"Gzil","year":"2020","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.002_bib0077","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41588-020-00748-0","article-title":"Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction [published correction appears in Nat Genet. 2021 Jan 20;:]","volume":"53","author":"Conti","year":"2021","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.urolonc.2024.06.002_bib0078","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.ajhg.2023.05.010","article-title":"Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry","volume":"110","author":"Darst","year":"2023","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.002_bib0079","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eururo.2023.01.022","article-title":"Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry","volume":"84","author":"Chen","year":"2023","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.002_bib0080","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12301-022-00273-y","article-title":"A comparison of clinicopathologic features of prostate cancer between Nigerian and South African black men","volume":"28","author":"Ahmed","year":"2022","journal-title":"Afr J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.06.002_bib0081","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/pros.23481","article-title":"Genetic risk of prostate cancer in Ugandan men","volume":"78","author":"Du","year":"2018","journal-title":"Prostate"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924005040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924005040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T11:15:36Z","timestamp":1732706136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924005040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1078143924005040"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.06.002","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review of family history, race\/ethnicity, and genetic risk on prostate cancer detection and outcomes: Considerations in PSA-based screening","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}